Key market opportunities in Q1 2026 include significant regulatory catalysts like approvals for GSK's depemokimab, Regenxbio's gene therapy, and Omeros' narsoplimab. Ongoing trials by Xenon, Cerevel, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results